-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
FSL-1-TFA
Category | Herpes simplex Virus (HSV) |
Description | FSL-1 TFA, a bacterial-derived toll-like receptor 2/6 (TLR2/6) agonist, enhances resistance to experimental HSV-2 infection. |
Product Information
Synonyms | FSL-1 (TFA)|CS-0130017 |
Molecular Weight | 1780.18 |
Molecular Formula | C82H141F3N14O20S |
Boiling Point | 1659.8±65.0 °C at 760 mmHg |
Flash Point | 957.6±34.3 °C |
Purity | 99.58% |
Density | 1.2±0.1 g/cm3 |
Solubility | In Vitro: H2O |
Appearance | White to off-white (Solid) |
Storage | Sealed storage, away from moisture and light Powder -80°C 2 years -20°C 1 years * In solvent -80°C 6 months -20°C 1 month (sealed storage, away from moisture and light) |
Index Of Refraction | 1.553 |
In Vitro | FSL-1 significantly reduces HSV-2 replication in human vaginal epithelial cells (EC). FSL-1 induces significant resistance to experimental genital HSV-2 infection through elaboration of a specific cytokine response profile. FSL-1 (50 ng/mL, 24 hours) induces MMP-9 expression at both mRNA and protein levels in human monocytic THP-1 cells. FSL-1 activates the MAP kinase/NF-κB signaling pathway. |
In Vivo | FSL-1 application significantly protectes against genital HSV-2 challenge in mice. |
Target | Toll-like Receptor (TLR); MMP; HSV; Antibiotic |
Vapor Pressure | 0.0±0.3 mmHg at 25°C |